Why take the continuous route? Because it leads to better, faster bioprocessing.
Sponsored By
Why adopt continuous bioprocessing? Because it can lead to faster and more cost-effective biopharma manufacturing. In this supplement, Pall and their collaborators discuss the benefits of continuous bioprocessing and how Pall is innovating in this area.
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
October 22, 2026
5 min read
Alcami’s Kerrie Powell, Senior VP of Sales, discusses the challenges of sterile biologics manufacturing and what sponsors should look for in a CDMO partner
October 22, 2026
5 min read
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
October 21, 2026
6 min read
Bristol Myers Squibb’s Robert Wethman discusses real-time spectroscopy, AI, and the next era of biopharmaceutical manufacturing
October 5, 2026
4 min read
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines